Drug intelligence / Profile preview

JW0104 + C2402

Development stage
Phase 3
Lead developer
JW Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

JW0104 + C2402 is an investigational **oral fixed-dose combination therapy** being developed for the treatment of **hypertension and dyslipidemia**. The combination consists of JW0104, a small molecule with clinical activity against cardiovascular and metabolic diseases, and C2402, a distinct compound whose pharmacological profile is being evaluated in tandem with JW0104[1][2][3][4][9][10]. Phase 1 studies have focused on safety and pharmacokinetics in healthy volunteers, and Phase 3 studies are underway (not yet recruiting, as of September 2025) to compare JW0104 + C2402 directly with other combinations and monotherapy in patients. The primary indication is the **joint management of high blood pressure (hypertension) and abnormal blood lipid levels (dyslipidemia)**. JW Pharmaceutical is leading development; mechanism of action details for the individual components are not publicly disclosed.

Brand names
JW0104 + C2402
Other names
JW0104 + C2402

Beyond the preview

Go deeper on JW0104 + C2402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW0104 + C2402.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call